Related Experiment Video
Updated: Jan 7, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Estimating the Global Macroeconomic Impact of Tuberculosis Among Children and Adolescents
Shun-Xian Zhang1, Qin-Yan Zuo1
1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Objectives:
Tuberculosis (TB) remains a major global health challenge. Understanding the economic burden of TB in adolescents is crucial for policy making, particularly in regions with limited healthcare resources.
Methods:
This study utilized disability-adjusted life-years from the Global Burden of Disease 2021 to estimate the economic impact of TB among adolescents (under 20 years of age) globally and regionally. Disability-adjusted life-years were monetized into Value of a Statistical Life-Year using the Value of a Statistical Life-Year framework, and macroeconomic data, including Gross Domestic Product (GDP) per capita (Purchasing Power Parity. Constant 2021 international dollars) from the World Bank, were incorporated. The primary outcome was the total economic burden of TB, expressed as the Value of Lost Welfare (VLW).
Results:
In 2021, the global economic burden of TB among adolescents was estimated at $262.98 billion (95% uncertainty interval, UI: 198.14, 350.17), or 0.17% of global GDP (95% UI: 0.13, 0.23). The burden was high in low- and lower-middle-income regions, with VLW in low-middle sociodemographic index regions reaching $153.92 billion (2.22% of GDP). In sub-Saharan Africa, VLW was $114.40 billion (2.37% of GDP). In contrast, high-income regions, such as North America and Western Europe, had much low VLWs (less than 0.01% of GDP). Thirteen countries had VLWs exceeding $5.00 billion, with India having the highest at $82.49 billion.
Conclusions:
The study highlights significant regional disparities, with particularly high burdens in low- and middle-income regions. It emphasizes the need for targeted investments in TB control in these areas.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories: